Metformin in the treatment of patients with non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 5, 2004, Pages 537-544

  Uygun, A ^a   Kadayifci, A ^b,c   Isik, A T ^a   Ozgurtas, T ^a   Deveci, S ^a   Tuzun, A ^a   Yesilova, Z ^a   Gulsen, M ^a   Dagalp, K ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c Fevzi Cakmak Bulv ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CLOFIBRATE; GEMFIBROZIL; INSULIN; METFORMIN; ROSIGLITAZONE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALORIC RESTRICTION; CLINICAL ARTICLE; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER NECROSIS; LOW FAT DIET; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; FEMALE; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; STEATORRHEA; TREATMENT OUTCOME;

EID: 1642296465     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01888.x     Document Type: Article

References (23)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis. Association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
3. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-8.
4. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996; 80: 1147-63.
5. Laurin J, Lindor K, Crippin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
6. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-9.
7. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
8. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
9. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
10. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-40.
11. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl A. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 2000; 6: 998-1003.
12. Marchesini G, Brizi M, Bianchi G, Tomasetti S, Zoli M, Melachionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
15. Withers CE, Wilson SR. The liver. In: Rumack CM, Wilson SR, Charboneau JW, eds. Diagnostic Ultrasound, 2nd edn. St Louis, MO: CV Mosby, 1998: 110-2.
16. Brunt AM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri B, Bacon B. Nonalcoholic steatohepatitis. A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
17. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
18. Solomon SS, Mishra SK, Cwik C, Rajanna B, Postlethwaite AE. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 1997; 29: 370-82.
19. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
20. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
21. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
22. Misbin R, Green L, Stadel B, Gueriguian J, Gubbi A, Fleming G. Lactic acidosis in patients with diabetes mellitus with metformin. N Engl J Med 1998; 338: 265-6.
23. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes Obes Metab 2001; 3: 195-201.